AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

TELIX PHARMACEUTICALS LTD

17.500

+0.4802.82%

Volume:3.35M

Turnover:58.41M

Market Cap:5.92B

PE:121.02

High:17.750

Open:17.060

Low:16.880

Close:17.020

52wk High:31.970

52wk Low:16.000

Shares:338.38M

Float Shares:275.41M

Volume Ratio:1.21

T/O Rate:1.22%

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.145

EPS(LYR):0.151

ROE:13.92%

ROA:5.33%

PB:10.42

PE(LYR):116.12

Loading ...

Overview Company News Filings

5 ASX shares for growth investors to buy with $10,000 in May

Telix Pharmaceuticals Ltd. Sees Minimal Impact from New U.S. Drug Pricing Regulation, Prioritizes U.S. Market Strategy

3 ASX 200 shares for smart investors to buy

Which ASX All Ords stock recently became a 10-bagger in 5 years?

Telix Says Publication of Thyroid Cancer Therapy Candidate in American Thyroid Association Journal Validates Safety Profile

MT Newswires Live

BUZZ-Australian healthcare stocks at 1-week low on fears of hit to exports to US

Bell Potter names more of the best ASX 200 stocks to buy in May

How to invest: my 3 biggest ASX share dealbreakers

Here are the top 10 ASX 200 shares today

BRIEF-Illuccix Prostate Cancer Psma-Pet Imaging Agent Approved In Finland

Brokers tip 4 ASX 200 healthcare shares to buy now

BUZZ-ASX-listed Telix Pharmaceuticals rises; Morningstar expects regulatory approval for Pixclara

Telix Pharmaceuticals Secures Marketing Authorization for Prostate Cancer Imaging Agent in France

MT Newswires Live

Telix's Illuccix PSMA-PET Imaging Agent Approved in France

BUZZ-Morningstar expects FDA nod for Telix Pharmaceuticals' Pixclara to be delayed, not denied

5 things to watch on the ASX 200 on Tuesday

BUZZ-U.S. STOCKS ON THE MOVE-Marriott, Wells Fargo, Insulet

BUZZ-Telix Pharma dips as FDA rejects brain cancer imaging agent

Australian Shares Rise on Tech Rally; Telix Faces US FDA Setback

MT Newswires Live

BUZZ-ASX-listed Telix Pharmaceuticals stock tumbles after FDA denies Pixclara approval

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/TLX.AU/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TLX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"TLX.AU\",,,,,undefined,":{"symbol":"TLX.AU","market":"AU","secType":"STK","nameCN":"TELIX PHARMACEUTICALS LTD","latestPrice":17.5,"timestamp":1755238320000,"preClose":17.02,"halted":0,"volume":3350423,"delay":0,"nameEN":"TELIX PHARMACEUTICALS LTD","floatShares":275410996,"shares":338382614,"eps":0.1446,"marketStatus":"Not Yet Opened","change":0.48,"latestTime":"08-15 16:12:00 AEST","open":17.06,"high":17.75,"low":16.88,"amount":58409058,"amplitude":0.051116,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.1446,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1755475200000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":17.02,"openAndCloseTimeList":[[1755216000000,1755237600000]],"volumeRatio":1.206257880622531,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"TLX.AU\",,,,,undefined,":{"symbol":"TLX.AU","floatShares":275410996,"roa":"5.33%","roe":"13.92%","lyrEps":0.150709,"volumeRatio":1.206257880622531,"shares":338382614,"dividePrice":0,"high":17.75,"amplitude":0.051116,"preClose":17.02,"low":16.88,"week52Low":16,"pbRate":"10.42","psRate":"7.56","week52High":31.97,"institutionHeld":0,"latestPrice":17.5,"eps":0.1446,"divideRate":0,"volume":3350423,"delay":0,"ttmEps":0.1446,"open":17.06,"prevYearClose":24.61,"prevWeekClose":17.5,"prevMonthClose":21.05,"prevQuarterClose":24.42,"fiveDayClose":17.64,"twentyDayClose":25.26,"sixtyDayClose":25.25,"earningDate":1755705600000},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TLX.AU\",params:#limit:5,,,undefined,":[{"date":"2025-08-21","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1755734400000,"name":null,"time":"","dateTimestamp":1755698400000,"actualEps":null},{"date":"2025-02-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1739919600000,"name":null,"time":"","dateTimestamp":1739883600000,"actualEps":null},{"date":"2024-08-22","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724284800000,"name":null,"time":"","dateTimestamp":1724248800000,"actualEps":null},{"date":"2024-02-22","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1708556400000,"name":null,"time":"","dateTimestamp":1708520400000,"actualEps":null},{"date":"2023-10-18","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1697583600000,"name":null,"time":"","dateTimestamp":1697547600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TLX.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TLX.AU\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2535058131","title":"5 ASX shares for growth investors to buy with $10,000 in May","url":"https://stock-news.laohu8.com/highlight/detail?id=2535058131","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535058131?lang=en_us&edition=fundamental","pubTime":"2025-05-14 08:46","pubTimestamp":1747183560,"startTime":"0","endTime":"0","summary":"We're now in the middle of May, and after a rocky start to the quarter, the ASX has rebounded strongly in recent weeks. While some investors may be wondering if they've missed the moment, smart investors know this simple truth: it's never too late to invest in quality companies. In fact, when you're focused on the long term, the best opportunities often remain in plain sight — found in ASX shares with strong growth runways and proven execution. But which shares would be top buys for a $10,000 investment?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/05/14/5-asx-shares-for-growth-investors-to-buy-with-10000-in-may/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["IE0004086264.USD","LU1363072403.SGD","WTC.AU","IE00B19Z3B42.SGD","LU1720051017.SGD","LU1868836757.USD","LU0267386448.USD","BK4504","LU1548497426.USD","IE0034235188.USD","BK4585","LU1868837300.USD","LU0096364046.USD","LU2023251221.USD","XRO.AU","IE0002270589.USD","LU0106831901.USD","BK4534","LU1732800096.USD","NXT.AU","LU2237438978.USD","LU0048573561.USD","LU0912757837.SGD","LU1868836591.USD","IE0004091025.USD","LU0971096721.USD","LOV.AU","TLX.AU","LU0106261372.USD","LU0320765646.SGD","LU2750360997.AUD","LU0006306889.USD","LU1868837136.USD","IE00BKVL7J92.USD","LU0158827781.USD","LU0251131958.USD","BK4588","BK4581","LU2089284900.SGD","LU2237443622.USD","LU2471134879.HKD","LU1732799900.SGD","LU2089283258.USD","LU1668664300.SGD","BK4127","LU2471134523.USD","BK7128","BK4516","LU0795875169.SGD","LU1074936037.SGD"],"gpt_icon":0},{"id":"2535754584","title":"Telix Pharmaceuticals Ltd. Sees Minimal Impact from New U.S. Drug Pricing Regulation, Prioritizes U.S. Market Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2535754584","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535754584?lang=en_us&edition=fundamental","pubTime":"2025-05-13 10:35","pubTimestamp":1747103719,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telix Pharmaceuticals Ltd. published the original content used to generate this news brief on May 13, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250513:nNDL6SNJ7k:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TLX.AU"],"gpt_icon":0},{"id":"2534049657","title":"3 ASX 200 shares for smart investors to buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2534049657","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534049657?lang=en_us&edition=fundamental","pubTime":"2025-05-10 06:36","pubTimestamp":1746830160,"startTime":"0","endTime":"0","summary":"Smart investors know that long-term wealth isn't built on hype — it is built by owning quality businesses with real earnings power, global opportunity, and the ability to compound growth over time. Ri","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/05/10/3-asx-200-shares-for-smart-investors-to-buy/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7501","RMD.AU","JHX.AU","TLX.AU","BK7067","BK7044","BK7007"],"gpt_icon":0},{"id":"2534126073","title":"Which ASX All Ords stock recently became a 10-bagger in 5 years?","url":"https://stock-news.laohu8.com/highlight/detail?id=2534126073","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534126073?lang=en_us&edition=fundamental","pubTime":"2025-05-09 09:15","pubTimestamp":1746753310,"startTime":"0","endTime":"0","summary":"Supply Network has been around since 1976. It sells aftermarket truck and bus parts in Australia and New Zealand through its network of Multispares branches. The majority of its recent growth has come from its truck parts business.The company is supported by strong industry tailwinds, including Australia's ageing truck fleet, with the average truck nearly 15 years old. Trucks have also become increasingly complex in Australia, with up to 30,000 parts per vehicle. This has driven strong demand for the ASX All Ords company, with its 10-year compound annual revenue growth rate  sitting at around 14%. Recently, it has been even higher, delivering 18% revenue growth in the most recent half. Has the company peaked?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/05/09/which-asx-all-ords-stock-recently-became-a-10-bagger-in-5-years/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["XAO.AU","BK7086","TLX.AU","PME.AU","XKO.AU","SNL.AU","BK7508","BK7511","CAGR","BK7094","BK4159","BK7501","CSL.AU","XJO.AU","BK7067"],"gpt_icon":0},{"id":"2533971999","title":"Telix Says Publication of Thyroid Cancer Therapy Candidate in American Thyroid Association Journal Validates Safety Profile","url":"https://stock-news.laohu8.com/highlight/detail?id=2533971999","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533971999?lang=en_us&edition=fundamental","pubTime":"2025-05-08 08:42","pubTimestamp":1746664929,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (ASX:TLX) said Thursday that its fibroblast-activation-protein-targeting therapy candidate, TLX400, was published in Thyroid, the official journal of the American Thyroid Associa","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4117","TLX.AU","BK7067","BK4107","AFG"],"gpt_icon":0},{"id":"2533646680","title":"BUZZ-Australian healthcare stocks at 1-week low on fears of hit to exports to US","url":"https://stock-news.laohu8.com/highlight/detail?id=2533646680","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533646680?lang=en_us&edition=fundamental","pubTime":"2025-05-07 11:28","pubTimestamp":1746588492,"startTime":"0","endTime":"0","summary":"BUZZ-Australian healthcare stocks at 1-week low on fears of hit to exports to US** Australian healthcare stocks .AXHJ slip 1.2% to a one-week low, extending declines from previous session** Vaccine maker CSL CSL.AX down 1.8%; biopharma Telix TLX.AX drops 3.3%** US President Trump signs executive order aiming to reduce approval time for local pharma plants to encourage domestic manufacturing; plans pharma tariffs in next two weeks** Australian healthcare firms largely depend on exports to the U.S. and are hurt by a strong Australian dollar, which has hit a new five-month peak. AUD/  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250507:nL4N3RF0CY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7501","BK7508","CSL.AU","TLX.AU","BK7511"],"gpt_icon":0},{"id":"2533583644","title":"Bell Potter names more of the best ASX 200 stocks to buy in May","url":"https://stock-news.laohu8.com/highlight/detail?id=2533583644","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533583644?lang=en_us&edition=fundamental","pubTime":"2025-05-05 13:05","pubTimestamp":1746421514,"startTime":"0","endTime":"0","summary":"If you are looking for some new additions to your portfolio in May, then the ASX 200 stocks listed below could be worth a closer look. That's because they have been named onBell Potter'sAustralian Equ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/05/05/bell-potter-names-more-of-the-best-asx-200-stocks-to-buy-in-may/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7155","BK7510","BK7099","BK7067","CAGR","TLX.AU","BK4159","GMG.AU"],"gpt_icon":0},{"id":"2533832923","title":"How to invest: my 3 biggest ASX share dealbreakers","url":"https://stock-news.laohu8.com/highlight/detail?id=2533832923","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533832923?lang=en_us&edition=fundamental","pubTime":"2025-05-05 06:00","pubTimestamp":1746396000,"startTime":"0","endTime":"0","summary":"I believe investing in ASX shares is one of the best decisions that Aussies can make. However, I wouldn't invest in every ASX share. There are certain sectors and types of businesses that I'd avoid in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/05/05/how-to-invest-my-3-biggest-asx-share-dealbreakers/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7508","BK7511","BK7067","TLX.AU","CSL.AU","BK7501"],"gpt_icon":0},{"id":"2532692829","title":"Here are the top 10 ASX 200 shares today","url":"https://stock-news.laohu8.com/highlight/detail?id=2532692829","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532692829?lang=en_us&edition=fundamental","pubTime":"2025-05-02 15:03","pubTimestamp":1746169416,"startTime":"0","endTime":"0","summary":"The S&P/ASX 200 Index (ASX: XJO) enjoyed a strong finish this Friday in what has been a strong week for the share market. By the time the closing bell rang, the ASX 200 had jumped up a healthy 1.13%. ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/05/02/here-are-the-top-10-asx-200-shares-today-02-may-2025/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["LNW.AU","BK7145","BK7096","BOE.AU","IEL.AU","SMR.AU","TLX.AU","BK7095","XJO.AU","NIC.AU","BK7126","BK7129","BK7067","PNV.AU","CU6.AU","LIC.AU","NEU.AU","BK7132","BK7083","BK7078","BK7508"],"gpt_icon":0},{"id":"2531777462","title":"BRIEF-Illuccix Prostate Cancer Psma-Pet Imaging Agent Approved In Finland","url":"https://stock-news.laohu8.com/highlight/detail?id=2531777462","media":"Reuters","labels":["productRelease","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531777462?lang=en_us&edition=fundamental","pubTime":"2025-04-30 14:58","pubTimestamp":1745996297,"startTime":"0","endTime":"0","summary":"BRIEF-Illuccix Prostate Cancer Psma-Pet Imaging Agent Approved In FinlandApril 30 (Reuters) - Telix Pharmaceuticals Ltd TLX.AX:ILLUCCIX PROSTATE CANCER PSMA-PET IMAGING AGENT APPROVED IN FINLANDTELIX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250430:nTUA3XYBSM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"BRIEF-Illuccix Prostate Cancer Psma-Pet Imaging Agent Approved In Finland","news_tag":"productRelease,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TLX.AU"],"gpt_icon":0},{"id":"2531227449","title":"Brokers tip 4 ASX 200 healthcare shares to buy now","url":"https://stock-news.laohu8.com/highlight/detail?id=2531227449","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531227449?lang=en_us&edition=fundamental","pubTime":"2025-04-29 15:05","pubTimestamp":1745910347,"startTime":"0","endTime":"0","summary":"ASX 200 healthcare shares finished in the green on Tuesday, with the S&P/ASX 200 Health Care Index  lifting 0.61%.  Healthcare is seen as a defensive sector.  In today's turbulent market, perhaps you might be looking for buying opportunities?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/29/brokers-tip-4-asx-200-healthcare-shares-to-buy-now/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7124","BK7509","BK7508","BK7511","CSL.AU","HLS.AU","BK7501","TLX.AU","RMD.AU","BK7007","BK7067"],"gpt_icon":0},{"id":"2531499872","title":"BUZZ-ASX-listed Telix Pharmaceuticals rises; Morningstar expects regulatory approval for Pixclara","url":"https://stock-news.laohu8.com/highlight/detail?id=2531499872","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531499872?lang=en_us&edition=fundamental","pubTime":"2025-04-29 12:15","pubTimestamp":1745900157,"startTime":"0","endTime":"0","summary":"BUZZ-ASX-listed Telix Pharmaceuticals rises; Morningstar expects regulatory approval for Pixclara Updates with share moves** Shares of Telix Pharmaceuticals TLX.AX rise 2.8% to A$27.44** Morningstar a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nL4N3R7088:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK7067"],"gpt_icon":0},{"id":"2531291299","title":"Telix Pharmaceuticals Secures Marketing Authorization for Prostate Cancer Imaging Agent in France","url":"https://stock-news.laohu8.com/highlight/detail?id=2531291299","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531291299?lang=en_us&edition=fundamental","pubTime":"2025-04-29 07:49","pubTimestamp":1745884196,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals  received marketing authorization in France for Illuccix, its prostate cancer positron emission tomography  imaging agent, the company said in a statement Monday.Illucix is indicated in France for the detection and localization of prostate-specific membrane antigen-positive lesions in adults with prostate cancer, the statement said.The company is partnering with IRE Group subsidiary IRE ELiT to market and promote Illuccix in France, according to the statement.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7047","PET.AU","BK7067","TLX.AU","BK4192","PET","TLX"],"gpt_icon":0},{"id":"2531999262","title":"Telix's Illuccix PSMA-PET Imaging Agent Approved in France","url":"https://stock-news.laohu8.com/highlight/detail?id=2531999262","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531999262?lang=en_us&edition=fundamental","pubTime":"2025-04-29 06:30","pubTimestamp":1745879400,"startTime":"0","endTime":"0","summary":"New approval provides French hospitals and clinics with access to a provenPSMA-PET imaging agent. MELBOURNE, Australia, April 29, 2025  -- Telix Pharmaceuticals Limited  today announces that its prostate cancer PET1 imaging agent, Illuccix , has been granted marketing authorization in France by ANSM2 for the detection and localization of prostate-specific membrane antigen -positive lesions in adults with prostate cancer, a broad clinical label.Illuccix, after radiolabelling with gallium-68, is indicated in France for the detection of prostate-specific membrane antigen -positive lesions with PET in adults with prostate cancer  in the following clinical settings:. Identification of patients with PSMA-positive progressive metastatic castration-resistant prostate cancer  for whom PSMA-targeted therapy is indicated.With its broad indication and ready-to-use formulation, Illuccix is designed to support healthcare providers in delivering efficient and reliable imaging. The approval comes as d","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/telixs-illuccix-psma-pet-imaging-223000028.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ASX","PSA","UK","BK4139","BK4084","DCP","CE","BK4192","TLX","TLX.AU","BK4109","BK4528","TGA","BK4233","BK4213","PET","BCR","BK4217","BK4543","BK4205","BK4144","BK4585","BK4141","BK4533","EEA","BK4526","BK4588"],"gpt_icon":0},{"id":"2531155264","title":"BUZZ-Morningstar expects FDA nod for Telix Pharmaceuticals' Pixclara to be delayed, not denied","url":"https://stock-news.laohu8.com/highlight/detail?id=2531155264","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531155264?lang=en_us&edition=fundamental","pubTime":"2025-04-29 05:21","pubTimestamp":1745875276,"startTime":"0","endTime":"0","summary":"BUZZ-Morningstar expects FDA nod for Telix Pharmaceuticals' Pixclara to be delayed, not denied** Morningstar analysts expect Telix Pharmaceuticals TLX.AX to receive a delayed regulatory approval, inst","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250428:nL4N3R61SW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TLX.AU"],"gpt_icon":0},{"id":"2531295005","title":"5 things to watch on the ASX 200 on Tuesday","url":"https://stock-news.laohu8.com/highlight/detail?id=2531295005","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531295005?lang=en_us&edition=fundamental","pubTime":"2025-04-29 04:54","pubTimestamp":1745873649,"startTime":"0","endTime":"0","summary":"On Monday, theS&P/ASX 200 Index started the week in a positive fashion. The benchmark index rose 0.35% to 7,997.1 points. Will the market be able to build on this on Tuesday?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/29/5-things-to-watch-on-the-asx-200-on-tuesday-29-april-2025/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7142","RRL.AU","BK7095","TLX.AU","KAR.AU","XJO.AU","BK7104","BK7067","EVN.AU","BK7507","BK7506","LYC.AU","STO.AU"],"gpt_icon":0},{"id":"2530231194","title":"BUZZ-U.S. STOCKS ON THE MOVE-Marriott, Wells Fargo, Insulet","url":"https://stock-news.laohu8.com/highlight/detail?id=2530231194","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530231194?lang=en_us&edition=fundamental","pubTime":"2025-04-28 23:51","pubTimestamp":1745855481,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Marriott, Wells Fargo, InsuletEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: htt","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250428:nL4N3R61IT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVD2.UK","NVIW.SI","MTD","ADMA","LU2063271972.USD","NVD","NEM","NVDY","NVDX","CGON","NVDD","3NVD.UK","SAG","SWTX","TLX.AU","NVDU","NVD3.UK","SABR","2NVD.UK","BHVN","AZUL","AMPY","NVDS","RVTY","MAR","CNC","GLMD","SPCB","WY","PODD","SPRB","WOLF","INTJ","VLRS","IE00B7SZLL34.SGD","TSYW.SI","SPRBX","SNVD.UK","NVDS.UK","EAF","DPZ","OPRA","PLUG","RBOT"],"gpt_icon":1},{"id":"2530159238","title":"BUZZ-Telix Pharma dips as FDA rejects brain cancer imaging agent","url":"https://stock-news.laohu8.com/highlight/detail?id=2530159238","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530159238?lang=en_us&edition=fundamental","pubTime":"2025-04-28 22:49","pubTimestamp":1745851762,"startTime":"0","endTime":"0","summary":"BUZZ-Telix Pharma dips as FDA rejects brain cancer imaging agent** U.S.-listed shares of Australia's Telix Pharmaceuticals TLX.AX, TLX.O fall 7.8% to $17.35** Late on Sunday, co said the US FDA declined to approve its marketing application for Pixclara, an imaging agent for glioma brain cancer** TLX said FDA has requested additional clinical evidence to progress the application, stating that the application cannot be approved in its current form** An imaging agent is a substance used in medical scans to enhance the visibility of internal body structures** Co said it plans to request a hearing with the FDA to understand the decision and explore ways to supplement their application** The rejection does not affect the company's financial forecasts for 2025, co said** Including session move, stock up 8.4% YTD","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250428:nL4N3R61FP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK7067"],"gpt_icon":0},{"id":"2530544555","title":"Australian Shares Rise on Tech Rally; Telix Faces US FDA Setback","url":"https://stock-news.laohu8.com/highlight/detail?id=2530544555","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530544555?lang=en_us&edition=fundamental","pubTime":"2025-04-28 14:40","pubTimestamp":1745822421,"startTime":"0","endTime":"0","summary":"Australian shares continued to rally on Monday, led by the information technology sector, with all but one sector trading in the green.The S&P/ASX 200 Index rose 28.90 points, or 0.36%, to 7,997.10.Th","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7002","DHG.AU","JHX.AU","TLX.AU","BK7067","XKO.AU","BK7039","BK7503","BK7044","XAO.AU","XJO.AU","ASX.AU"],"gpt_icon":0},{"id":"2530963418","title":"BUZZ-ASX-listed Telix Pharmaceuticals stock tumbles after FDA denies Pixclara approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2530963418","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530963418?lang=en_us&edition=fundamental","pubTime":"2025-04-28 11:21","pubTimestamp":1745810462,"startTime":"0","endTime":"0","summary":"BUZZ-ASX-listed Telix Pharmaceuticals stock tumbles after FDA denies Pixclara approval** Shares of Telix Pharmaceuticals TLX.AX fall 6% to A$26.86, their lowest since April 14** Stock among the bigges","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250428:nL4N3R6094:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TLX.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":8,"pageCount":4,"totalSize":160,"code":"91000000","status":"200"}]}}